126 related articles for article (PubMed ID: 38115179)
1. KLK10 promotes the progression of KRAS mutant colorectal cancer via PAR1-PDK1-AKT signaling pathway.
Wu K; Wu B; Yan K; Ding Q; Miao Z
Cell Biol Int; 2024 Apr; 48(4):440-449. PubMed ID: 38115179
[TBL] [Abstract][Full Text] [Related]
2. Kallikrein-related peptidase (KLK10) cessation blunts colorectal cancer cell growth and glucose metabolism by regulating the PI3K/Akt/mTOR pathway.
Wei H; Dong C; Shen Z
Neoplasma; 2020 Jul; 67(4):889-897. PubMed ID: 32386481
[TBL] [Abstract][Full Text] [Related]
3. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
4. NES1/KLK10 promotes trastuzumab resistance via activation of PI3K/AKT signaling pathway in gastric cancer.
Tang L; Long Z; Zhao N; Feng G; Guo X; Yu M
J Cell Biochem; 2018 Aug; 119(8):6398-6407. PubMed ID: 29231994
[TBL] [Abstract][Full Text] [Related]
5. Andrographolide sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the EGFR/AKT and PDGFRβ/AKT signaling pathways.
Liu YF; Feng ZQ; Chu TH; Yi B; Liu J; Yu H; Xue J; Wang YJ; Zhang CZ
Phytomedicine; 2024 Apr; 126():155462. PubMed ID: 38394734
[TBL] [Abstract][Full Text] [Related]
6. 3-phosphoinositide-dependent kinase 1 controls breast tumor growth in a kinase-dependent but Akt-independent manner.
Gagliardi PA; di Blasio L; Orso F; Seano G; Sessa R; Taverna D; Bussolino F; Primo L
Neoplasia; 2012 Aug; 14(8):719-31. PubMed ID: 22952425
[TBL] [Abstract][Full Text] [Related]
7. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.
Lee HW; Son E; Lee K; Lee Y; Kim Y; Lee JC; Lim Y; Hur M; Kim D; Nam DH
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771279
[TBL] [Abstract][Full Text] [Related]
8. Long noncoding RNA SNHG14 accelerates cell proliferation, migration, invasion and suppresses apoptosis in colorectal cancer cells by targeting miR-944/KRAS axis through PI3K/AKT pathway.
Pei Q; Liu GS; Li HP; Zhang Y; Xu XC; Gao H; Zhang W; Li T
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9871-9881. PubMed ID: 31799655
[TBL] [Abstract][Full Text] [Related]
9. Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells.
Song Q; Sun X; Guo H; Yu Q
Oncotarget; 2017 Jan; 8(3):5003-5015. PubMed ID: 28002807
[TBL] [Abstract][Full Text] [Related]
10. p53-armed oncolytic adenovirus induces autophagy and apoptosis in KRAS and BRAF-mutant colorectal cancer cells.
Tamura S; Tazawa H; Hori N; Li Y; Yamada M; Kikuchi S; Kuroda S; Urata Y; Kagawa S; Fujiwara T
PLoS One; 2023; 18(11):e0294491. PubMed ID: 37972012
[TBL] [Abstract][Full Text] [Related]
11. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
[TBL] [Abstract][Full Text] [Related]
12. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH
BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218
[TBL] [Abstract][Full Text] [Related]
13. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
14. Osthole inhibits malignant phenotypes and induces ferroptosis in KRAS-mutant colorectal cancer cells via suppressing AMPK/Akt signaling.
Zhou X; Kang J; Zhang L; Cheng Y
Cancer Chemother Pharmacol; 2023 Aug; 92(2):119-134. PubMed ID: 37318525
[TBL] [Abstract][Full Text] [Related]
15. Aberrant upregulation of KLK10 promotes metastasis via enhancement of EMT and FAK/SRC/ERK axis in PDAC.
Cao XY; Zhang XX; Yang MW; Hu LP; Jiang SH; Tian GA; Zhu LL; Li Q; Sun YW; Zhang ZG
Biochem Biophys Res Commun; 2018 May; 499(3):584-593. PubMed ID: 29621546
[TBL] [Abstract][Full Text] [Related]
16. Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status.
Lee J; Jain A; Kim P; Lee T; Kuller A; Princen F; In-GuDo ; Kim SH; Park JO; Park YS; Singh S; Kim HC
PLoS One; 2014; 9(8):e103551. PubMed ID: 25090459
[TBL] [Abstract][Full Text] [Related]
17. Molecular Pathways Associated with Kallikrein 6 Overexpression in Colorectal Cancer.
Pandey R; Zhou M; Chen Y; Darmoul D; Kisiel CC; Nfonsam VN; Ignatenko NA
Genes (Basel); 2021 May; 12(5):. PubMed ID: 34065672
[TBL] [Abstract][Full Text] [Related]
18. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
[TBL] [Abstract][Full Text] [Related]
19. KLK8 promotes the proliferation and metastasis of colorectal cancer via the activation of EMT associated with PAR1.
Hua Q; Sun Z; Liu Y; Shen X; Zhao W; Zhu X; Xu P
Cell Death Dis; 2021 Sep; 12(10):860. PubMed ID: 34552064
[TBL] [Abstract][Full Text] [Related]
20. Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.
Wang Z; Kang B; Gao Q; Huang L; Di J; Fan Y; Yu J; Jiang B; Gao F; Wang D; Sun H; Gu Y; Li J; Su X
Cancer Sci; 2021 Sep; 112(9):3895-3910. PubMed ID: 34185934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
